Chang, L.C., Haggstrom, A.N., Drolet, B.A., Baselga, E., Chamlin, S.L., Garzon, M.C., Horii, K.A., Lucky, A.W., Mancini, A.J., Metry, D.W., Nopper, A.J., Frieden, I.J., et al. (2008) Growth Characteristics of Infantile Hemangiomas: Implications for Management. Pediatrics, 122, 360-367.
http://dx.doi.org/10.1542/peds.2007-2767

has been cited by the following article:

• TITLE: Oral Propranolol: A Useful Treatment for Infantile Hemangioma

  AUTHORS: Ahmed Hassan El-Sabbagh

  KEYWORDS: Oral Propranolol, Infantile Hemangioma, Medical Treatment

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.8 No.7, July 20, 2015

  ABSTRACT: Background: Infantile haemangioma is the commonest childhood tumor. Several lines of treatment are available. Recent reports have focused on the value of propranolol in treating rapidly proliferating haemangioma. The aim of this study was to assess oral propranolol in treatment for facial haemangioma. Patients and Methods: Fifteen patients with rapidly proliferating infantile facial haemangioma with cosmetic disfigurement were treated with oral propranolol. All patients had cardiovascular pre-treatment work-up and commenced on oral propranolol at 3 mg/kg/day. Results: A rapid decrease in hemangioma proliferation was seen in 100% of patients and significant regressions occuring in all patients. This treatment was well tolerated and had little side effects. Conclusions: Oral propranolol is a reliable and easily reproducible method for treatment of facial hemangioma.